An Oncologist’s Perspective on Future Treatment Options for the Profiled Patient and Targeted Treatment Approaches in R/R DLBCL
An oncologist shares which treatment regimen he would recommend next for this patient with DLBCL who experienced two disease relapses and reflects on how CD19- and CD79b-targeted therapies have impacted patient outcomes in the field.
EP: 1.Introduction: A 68-Year-Old Man with Diffuse Large B-Cell Lymphoma
EP: 2.Second-Line Treatment Approaches for R/R DLBCL
EP: 3.Available Treatment Options in DLBCL with 2 or More Relapses
EP: 4.An Oncologist’s Perspective on Future Treatment Options for the Profiled Patient and Targeted Treatment Approaches in R/R DLBCL
EP: 5.Critical Unmet Needs in DLBCL
Later-Line CD19 and Bispecific Therapies Considered After CAR T
October 1st 2024During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed third- and fourth-line therapy and barriers to bispecific therapy use in diffuse large B-cell lymphoma in the second article of a 2-part series.
Read More
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Superior Outcomes With Brentuximab Vedotin Triplet in Diffuse Large B-Cell Lymphoma
September 11th 2024The addition of brentuximab vedotin to lenalidomide and rituximab significantly improved survival and response vs lenalidomide/rituximab alone in patients with relapsed/refractory DLBCL.
Read More
